Background: In older adults, thyroid-stimulating hormone (TSH) concentrations are raised and higher free thyroxine (FT4) is associated with poorer health outcomes. As use of nonage-appropriate reference ranges could lead to suboptimal management, we aimed to define reference intervals for TSH and FT4 in older men. Methods: We conducted the study on community-dwelling men aged 70-89 years. Baseline TSH and FT4 levels were assayed (Elecsys 2010, Roche Diagnostics). Conventional reference intervals for TSH and FT4 were 0.4-4.0 mIU/L and 10-23 pmol/L, respectively. Incident deaths were ascertained using data linkage. Results: Of the 3,885 men included in the analysis, the 2.5th and 97.5th centiles for TSH and FT4 were 0.64-5.9 mIU/L and 12.1-20.6 pmol/L (0.94-1.60 ng/dL), respectively. Of the 411 very healthy men defined by excellent or very good self-rated health and absence of major medical comorbidities, 2.5th to 97.5th centiles for TSH and FT4 were 0.67-4.98 mIU/L and 12.1-20.5 pmol/L (0.94-1.59 ng/dL), respectively. TSH was not associated with mortality, whereas higher FT4 was associated with increased mortality. Applying intervals based on very healthy older men to the cohort as a whole led to the reclassification of 310 men (8.0%). More men were classified as being hyperthyroid or hypothyroid, or having subclinical hyperthyroidism, and fewer as having subclinical hypothyroidism. Conclusions: In older men, the reference interval for TSH in older men is shifted upward, whereas the reference interval for FT4 is compressed compared with the conventional reference ranges. Applying reference intervals based on healthy older men identifies a substantial number of older men as having overt thyroid disease or subclinical hyperthyroidism and reduces the number classified as having subclinical hypothyroidism.
The thyroid axis matures during ageing, with older adults exhibiting higher thyrotrophin/thyroid-stimulating hormone (TSH) concentrations compared with younger and middle-aged adults (1) . With increasing age, TSH distributions shift to the right and mean TSH increases (1) (2) (3) . There is a parallel increase in free thyroxine (FT4) with age, albeit of smaller magnitude compared with TSH (4, 5) . Lower TSH within the reference range predicts incidence of hip fracture in women aged ≥65 years (6) , whereas in older men higher FT4 within the reference range is associated with frailty (4) and incidence of dementia (7) . Higher FT4 is also associated with fatigue (8) and with increased mortality in later life (9, 10) . Conversely adaptation of the pituitarythyroid axis, manifesting as higher TSH and lower FT4 and free triiodothyronine concentrations, is associated with familial longevity (11) . This increasing evidence relating differences in thyroid function with poorer health outcomes prompts reconsideration of the "normal" or reference intervals for not only TSH but also FT4 in older adults.
Subclinical hyperthyroidism, characterized by subnormal TSH in the presence of normal FT4, is associated with increased risk of atrial fibrillation and mortality from coronary heart disease (12) . Subclinical hypothyroidism, an elevated TSH in the presence of normal FT4, is associated with increased risk of coronary heart disease and stroke, particularly at higher concentrations of TSH (13, 14) . These definitions of subclinical thyroid disease rely on the applicability of existing normal or reference ranges for FT4 and TSH respectively. However, reference intervals tend to be assay specific and generally are based on laboratory protocols and validation studies undertaken by manufacturers in healthy adults (15, 16) . Use of nonage-appropriate reference ranges could lead to errors in identifying thyroid dysfunction where no pathology exists leading to overtreatment; and potentially cause serious thyroid abnormalities to be overlooked. The utility and consequences of applying reference intervals derived from older adults to the identification of overt or subclinical thyroid dysfunction in this demographic is uncertain. In this study, we determined reference intervals for TSH and FT4 in a population-based cohort of older men and ascertained the effect of applying age-appropriate reference intervals to the classification of overt and subclinical disease.
Methods

Study Population
The Health In Men Study is a population-based cohort study of community-dwelling older men in Perth, Western Australia (17) . A total of 12,203 predominantly Caucasian men completed a questionnaire and attended a screening medical examination in Wave 1 (W1; 1996-1999). In Wave 2, (W2; 2001-2004), 4,248 of these men, then aged 70-89 years, completed a second questionnaire, attended for physical examination, and provided an early morning blood sample. The study was approved by the University of Western Australia Human Research Ethics Committee, and all men provided informed consent to participate.
Assessment of Medical Comorbidities
Demographic, physical, medical, and medications data were collected by questionnaire, and height, weight, and blood pressure were measured at W2. Men were considered to have hypertension if they reported this diagnosis at W1 or W2 or used antihypertensive medication or had blood pressure ≥140/90 mmHg at W2. Dyslipidemia was defined as having fasting high-density lipoprotein <0.9 mmol/L, lowdensity lipoprotein ≥3.4 mmol/L, triglycerides ≥1.8 mmol/L, or total cholesterol ≥5.5 mmol/L or receiving lipid-lowering therapy at W2. Men diagnosed with diabetes, reporting use of glucose-lowering medication, or with fasting or nonfasting glucose at W2 of ≥7.0 mmol/L or ≥11.1 mmol/L, respectively, were considered to have diabetes.
Assessment of All-Cause Mortality
Mortality was assessed using the Western Australian Data Linkage System, which provides electronic linkage to records from death, hospital, and cancer registries and captures admissions to all public and private hospitals in Western Australia (18) . Prevalent cardiovascular disease was defined as self-reported history of angina, acute myocardial infarction, stroke, or abdominal aortic aneurysm by questionnaire responses in W1 and W2 or hospital diagnoses of these conditions prior to W2. Cancer diagnoses were identified from the cancer registry between 1990 and W2. Dementia was assessed by medical history and hospital admissions data up to W2. Depression was classified according to mental health and hospital morbidity data up to W2 or by a score of 7 or more on the Geriatric Depression Scale administered at W2 (19) .
Exclusion of Known Thyroid Disease
Questionnaire data at W1 and W2 were evaluated to identify men with existing thyroid diseases at baseline including use of thyroidrelated medications. In addition, we used Western Australian Data Linkage System to ascertain the presence of thyroid disorders (4). Data were collected from 1990 to the time of blood sampling to provide an indication of past and current disease. The following thyroid disorders (ICD-10 codes) were used to identify men with thyroid disorders: iodine deficiency (E00, E01, and E02), established hypothyroidism or hyperthyroidism (E03 and E05), thyroiditis (E06), nontoxic goiter (E04), and other specified disorders of thyroid (E07.8). The ICD-9 codes 240.x-246.x were also used for this purpose.
Defining Optimal Health in Older Men
We studied a sample of men of the W2 cohort who were considered to be in optimal health. Firstly, global perception of health was assessed at W2 with the question, "In general, would you say your health is …?" The five responses available were "excellent," "very good," "good," "fair," and "poor." This measure has been validated as a predictor of mortality in older men (20) . The subset of older men reporting "excellent" or "very good" health without diabetes, cardiovascular disease, cancer, depression, or dementia were considered to be in optimal health.
Laboratory Assays
Laboratory assays were performed on aliquots of serum and plasma prepared immediately after the collection of blood sampled during W2 and stored at −80°C until the time of assay, as described previously (4) . Briefly, serum TSH and plasma FT4 concentrations were measured using an Elecsys 2010 immunoanalyser (Roche Diagnostics, Australia). Between-run imprecision values (coefficient of variation) were for TSH 4.5% and 4.2% at 0.4 mIU/L and 5.0 mIU/l and for FT4 4.0% and 5.2% at 14 pmol/L (1.09 ng/dL) and 37 pmol/L (2.87 ng/dL). Reference intervals for these assays based on local clinical laboratory protocols were TSH 0.4-4.0 mIU/L and FT4 10-23 pmol/L (0.78-1.79 ng/dL). To convert FT4 in pmol/L to ng/dL, divided by 12.87.
Statistical Analysis
Statistical procedures were performed using GraphPad Prism® (version 6.05 for Windows; Graph Pad Software Inc, San Diego, CA) and R (21) . Statistical methodologies from published guidelines were applied to define TSH and FT4 reference intervals between the 2.5th to 97.5th centiles (22) . Outlying values were removed using Robust Regression and Outlier Removal with the coefficient Q set at 1% (23). Partitioning was not performed. Survival analysis was performed using standard methodology (R package: survival) and depicted graphically using Kaplan-Meier curves. Univariate associations were performed using the "survdiff" function and presented with log-rank p values. Cox proportional hazards regression was performed using a backward stepwise elimination approach with mortality from any cause as the outcome of interest. The optimal model was chosen using analysis of variance methods. In the analysis between quintiles, FT4 was retained a priori as the variable of interest. The values of p < .05 were considered significant for retention of other variables into the final model.
Results
Characteristics of the Study Population
After exclusion of men with known thyroid disease and men who were considered to have undiagnosed hyperthyroidism (TSH < 0.4 mU/L and FT4 > 23 pmol/L [>1.79 ng/dL]) or hypothyroidism (TSH > 4 mU/L and FT4 < 10 pmol/L [<0.78 ng/dL]), there were 3,885 men of whom 3,840 and 3,710 had TSH and FT4 concentrations available, respectively. Baseline characteristics of these men, and the subgroup classified as being in optimal health, are shown (Table 1) . Men in optimal health were younger, less likely to have hypertension or dyslipidemia and had a lower body mass index compared with the cohort as whole. Men in optimal health had TSH and FT4 concentrations comparable to the cohort as a whole.
Reference Intervals Based on 2.5th to 97.5th Centiles The 2.5th to 97.5th centiles in the entire cohort were 0.64-5.9 mIU/L for TSH and 12.1-20.6 pmol/L (0.94-1.60 ng/dL) for FT4, respectively. Of the 411 men in optimal health, 408 and 392 men had TSH and FT4 concentrations available, respectively. According to the predetermined methodology, 17 values in the TSH group were considered outliers (values of 5.5-12.5) and excluded from the reference interval calculation. Of the men in optimal health, the 2.5th to 97.5th centiles reference intervals were 0.67-4.98 mIU/L for TSH and 12.1-20.5 pmol/L (0.94-1.59 ng/ dL) for FT4. Applying these reference ranges to the cohort as a whole, there were n = 107 and n = 170 men with low and high TSH concentrations, respectively (2.8 and 4.4%), and n = 94 and n = 96 men with low and high FT4 concentrations, respectively (2.5 and 2.6%).
Defining Optimal TSH and FT4 Based on Mortality Risk
Numbers of men and the proportions who died during follow-up in each quintile (Q) of TSH and FT4 are shown (Supplementary Table 1 ). As mortality was lowest in men with TSH or FT4 values in the second quintile (Q2), Q2 was chosen as the baseline to compare other quintiles against in further analysis. For the analysis of mortality risk, none of the quintiles of TSH were significantly different to Q2 on log-rank testing ( Table 2) . As a result, TSH was not explored further in multivariate analyses. Hazard ratios from Cox proportional hazard models were calculated for FT4 (Table 2) . After adjustment for age, self-reported optimal health, cancer, cardiovascular disease, and history of lifelong nonsmoking, men with FT4 values in the highest quintile (Q5) had poorer survival than men in Q2 (Table 2 ). Of note, although the hazard ratios for Q5 were higher than for Q1, Q3, and Q4, the confidence intervals overlapped. Table 3 ). There were also 11 and 18 men newly classified as having "overt" hyperthyroidism and hypothyroidism, respectively. Six men were reclassified as having overt hyperthyroidism who were previously been regarded as having subclinical hyperthyroidism, and five men as having overt hyperthyroidism and 69 as having subclinical hyperthyroidism from men previously classified as euthyroid. Of the men previously regarded as having subclinical hypothyroidism, the new reference intervals reclassified 212 as being euthyroid and 18 as being overtly hypothyroid.
Reclassifying Men With Subclinical Hyperthyroidism and Subclinical Hypothyroidism
Discussion
In community-dwelling men aged 70-89 years, references intervals based on the 2.5th and 97.5th centiles in men regarded as having optimal health were higher for TSH (0.67-4.98 mIU/L) compared with Notes: Data are shown as median and interquartile ranges for continuous variables, and N (%) for categorical variables. BMI = body mass index; TSH = thyroid-stimulating hormone; FT4 = free thyroxine. Although men with FT4 in the highest quintile of values were at increased risk of dying from any cause, the separation between the highest quintile and the adjacent quintiles in terms of mortality risk was not sufficient to use this as a cutoff for the upper limit of FT4.
TSH is generally regarded as a sufficiently robust analyte that low cutoffs between 0.4 mIU/L and 0.45 mIU/L and high cutoffs between 4.0 mIU/L and 4.5 mIU/L have been used to define the reference range across different population samples using differing assay methodologies (12) (13) (14) . The desirability of defining abnormal thyroid hormone concentrations with greater precision in older adults is supported by the increase in TSH with age and the right shift in TSH distributions (1-3) . The change in TSH during ageing is gradual and subtle in magnitude, with increases in the order of 0.2-0.3 mIU/L over a decade (2, 3) . Nevertheless, demographic changes are resulting in older population profiles, where the likelihood of subclinical thyroid disease is relatively high (24) .
Our TSH reference interval for older men differs with those of previous studies. Kratzsch and coworkers using the Roche immunoassay studied 870 healthy blood donors reporting a reference interval for TSH based on 2.5th to 97.5th centiles of 0.30-3.63 mIU/L (15). Kussmaul and coworkers in a study of 967 men and 812 women aged 45-83 years defined a reference group of 1,002 adults who had no history of thyroid or other major systemic disease (16) . Using the Roche immunoassay, 2.5th to 97.5th centile ranges for TSH from that reference group were 0.24-2.84 mIU/L at age 45-55 years, 0.15-2.47 at 55-65 years, 0.11-2.77 at 65-75 years, and 0.1-2.01 at >75 years. Our results contrast with these findings, as the reference interval for TSH is consistently higher defined whether using the entire cohort of 3,885 men aged 70-89 years or using the 411 men with optimal health. We found that using the Roche immunoassay, healthy men aged 70 years and older can expect to have higher TSH concentrations between the range 0.67 mIU/L and 4.98 mIU/L. A higher reference interval for TSH is consistent with the study by Surks and Hollowell using the Access immunoassay (Beckman Instruments, USA) (2). In the National Health and Nutrition Survey among individuals with no history of thyroid disease the 97.5th centile for TSH increased from 4.02 mIU/L at age 20-29 years to 9.80 mIU/L at 70-79 years and from 3.56 to 5.90 mIU/L in the subset without serological evidence of thyroid autoimmunity (2). Ehrenkranz and coworkers conducted a retrospective analysis of thyroid hormone measurements in men across ≤20 to 80+ years of age using the Abbott Architect immunoassay finding stable 2.5th centiles for TSH between 0.53 mIU/L and 0.58, with an age-associated rise in the 97.5th centile from 5.42 mIU/L to 6.20 (25) . Thus, data from other populations using different TSH assay methodologies support the concept of a higher TSH reference interval in older men compared with younger and middle-aged men.
FT4 is technically more demanding to analyze, as more than 99.9% of circulating thyroxine is bound to thyroid-binding globulin or other carrier proteins, necessitating the use of back titration or labeled antibody methods to detect the unbound or free hormone (26). Kratzsch and coworkers using the Roche immunoassay reported reference intervals for FT4 based on 2.5th to 97.5th centiles of 12.7-20.8 pmol/L (0.99-1.61 ng/dL) for the cohort as a whole and 13.0-21.4 pmol/L (1.01-1.66 ng/dL) for men in the selected subgroup (15). Kussmaul and coworkers also using the Roche platform reported similar reference ranges for FT4 with little variation between the age of 45 years and 75 years and older (16) . These are reflected in updated recommendations from Roche (27) (25) .
Applying the new reference interval based on very healthy men to the cohort as a whole identified 2.8% of men with low and 4.4% of men with high TSH and 2.5% and 2.6% with low and high FT4, respectively. Men with FT4 in the highest quintile had an increased risk of death from any cause. However, the actual difference in mortality risk between men in the highest quintile and the two adjacent quintiles was not sufficient to define a cutoff for the upper limit of FT4. We postulate that for the purpose of defining abnormal thresholds potentially indicative of thyroid hyperfunction, the 97.5th centile in healthy older men (20.5 pmol/L [1.59 ng/dL]) would be appropriate.
Strengths of our study include the large cohort of communitydwelling older men, the availability of detailed medical and medications records to identify and exclude men with thyroid disease and the prospective follow-up for the outcome of all-cause mortality.
We adopted a standard methodology for determining reference intervals (22) and defined these in a reference group of very healthy older men. The characterization of our study population and sample size allows us to define reference intervals with reasonable precision. All men voluntarily attended a study center for venesection, making confounding from acute illness and sick euthyroid syndrome less likely.
We acknowledge several limitations of our study. Data were collected via questionnaires thus may be affected by recall bias. Although global perception of health was defined using self-report into five categories, this approach has been shown to predict outcomes such as mortality in older men (20) and subsequent development of frailty in middle-aged men (28) . Assays were performed on a single blood sample using a single assay methodology, albeit samples were collected early in the morning minimizing possible circadian variation in hormone concentrations (25) . In adults aged 65 years and older, mild TSH elevations in the range of 4.5-6.9 mIU/L can normalize over time, highlighting the value of repeated assessments for clinical evaluations (29) . Although we excluded men with existing thyroid disease, and those receiving thyroid-related medications, individuals may have been included who were on other medications that could affect the thyroid or TSH concentrations. We did not assay thyroid antibodies nor did we perform thyroid ultrasonography. Additional studies are warranted in differing populations that should encompass studies using different assays for TSH and FT4 and including stratification for the presence or absence of thyroid antibodies. Our study population comprised men who returned for the second wave of the Health In Men Study (17) , therefore a "healthy survivor" effect may be present. Western Australia is an iodine-sufficient region, (30) thus our findings may not apply to differing populations or to women. On this note, a gender effect has been postulated for TSH, with women having lower 2.5th centile and median values for TSH compared with men in the National Health and Nutrition Survey study (1) .
Applying these age-appropriate reference intervals derived from the subgroup of healthy older men to the cohort as a whole led to the reclassification of 310 men (8.0%). Six men previously regarded as having subclinical hyperthyroidism were reclassified as being overtly hyperthyroid, whereas from men previously classified as euthyroid, 5 were reclassified as overtly hyperthyroid and 69 as having subclinical hyperthyroidism. Conversely, of men previously regarded as having subclinical hypothyroidism, we reclassified 212 as being euthyroid and 18 as having overt hypothyroidism. Subclinical hyperthyroidism has been associated with atrial fibrillation and cardiovascular events, and more recently with fracture risk (12, 31) . Taking into consideration studies in older men associating higher FT4 with reduced mobility, frailty, fatigue, dementia, and mortality (4,7-10,32), raising the lower reference threshold for TSH and lowering the upper reference threshold for FT4 may help to identify more men with excess exposure to thyroid hormone, some of whom would be investigated for overt hyperthyroidism and considered for antithyroid therapy.
Reclassifying men previously regarded as being euthyroid as being overtly hyperthyroid or as having subclinical hyperthyroidism may provide an opportunity for treating hormone excess. However, caution is required as identifying more men as having hormone excess and using a narrower reference range to titrate antithyroid therapy could conceivably increase the risk of overtreatment. Conversely, subclinical hypothyroidism is a more common and heterogeneous entity particularly in older men (24) . Its associations with cardiovascular events are strongest at higher concentrations of TSH (13) and the benefits of intervention with thyroxine uncertain (33) . Of note, prescriptions for thyroid hormone therapy in older adults are increasing (34) . Raising the upper reference threshold for TSH and the lower threshold for FT4 reduces the proportion of men classified as having subclinical hypothyroidism. Potentially this may focus attention on a smaller number of men classified as having subclinical hypothyroidism, with higher TSH values who may be more at risk of associated morbidities. The age-appropriate reference range may also identify a number of men to be evaluated for overt hypothyroidism and considered for therapy on that basis.
In conclusion, in older men, the reference interval for TSH in older men is shifted upward to a range of 0.67-4.98 mIU/L, whereas the reference interval for FT4 is narrowed to 12.1-20.5 pmol/L (0.94-1.59 ng/dL) compared with the conventional reference ranges. Further studies are warranted to extend these findings to other populations and different TSH and FT4 assays and to determine whether applying age-appropriate reference ranges to the increasing demographic of older adults might improve the detection of overt and subclinical thyroid disease.
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